In the tumour agnostic cohort, ORR was 57% (95% CI, 35–77%) and median duration of response, PFS and overall survival were 12 months, 7 months and 14 months, respectively, validating RET as a tissue-agnostic target for RET inhibition, which is crucial for precision medicine in cancer. Here, RET is linked to cancer.